Markers of Bone Status in Diabetes Mellitus (Type 1 and Type 2)

Overview

Objective To collate the bone status in type 1 and type 2 diabetics using biochemical markers and bone scans. Methods: This is a multicenter trial involving the University Hospitals of three major danish cities: Aalborg, Aarhus and Odense. The trial is of cross-sectional design and consists of examinations including: – Blood samples to analyze bone markers, glycemic state, kidney function and sex-hormones. – 24 hour urine sample to analyze bone markers and kidney function. – Bone scans including dual energy x-ray absorptiometry (DXA) and high resolution peripheral quantitative computed tomography (HRpQCT) to evaluate Bone Mineral Density, t-score and bone structure. Participants: 100 type 1 diabetics and 100 type 2 diabetics recruited from outpatient clinics at Aalborg, Aarhus and Odense, general practitioners and flyers.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: December 2014

Detailed Description

Diabetes Mellitus and Osteoporosis are common conditions. Patients with Diabetes Mellitus are known to have more fractures than their non-diabetic counterparts. However bone mineral density (BMD) which is the most commonly used measure of fracture risk seems to be insensitive in diabetes, thus BMD is lowered in type 1 diabetes but not enough to explain an almost seven fold in fracture risk. BMD is increased in type 2 diabetes although they still have an increased fracture risk. The investigators investigate this paradox in diabetes by assessing type 1 and type 2 diabetes patients bone status by blood- and urine samples (assessing markers of bone- and glycemic state) and two types of bone scans comprising of DXA and HRpQCT scan. The diabetes mellitus patients are recruited from outpatients clinics in the three study sites (Aalborg, Aarhus and Odense) as well as general practitioners and by flyers and adds.

Arms, Groups and Cohorts

  • Diabetes Mellitus type 1
    • n=100
  • Diabetes Mellitus type 2
    • n=100

Clinical Trial Outcome Measures

Primary Measures

  • HbA1c
    • Time Frame: Baseline
    • Long term blood glucose evaluation
  • Bone Mineral Density (t-score)
    • Time Frame: Baseline

Secondary Measures

  • Biochemical Bone Markers
    • Time Frame: Baseline
  • Sex-hormones
    • Time Frame: Baseline
  • Electrolytes
    • Time Frame: Baseline
  • Vitamin D (25ODH /1,25OHD)
    • Time Frame: Baseline
  • Results from the HRpQCT scan including Trabecular and Cortical state
    • Time Frame: Baseline
    • Not available for participants at center Aalborg
  • Markers of fat tissue and glycemic status
    • Time Frame: Baseline
    • Including Insulin level, adiponectin
  • Verterbral fracture assessment
    • Time Frame: Baseline
    • A part of the DXA if vertebral fracture assessment is available. For patients at center Aalborg this will be evaluated through X-ray.
  • Lifestyle and Medical history
    • Time Frame: Baseline
    • Assessed by structured interview and questionnaire. Information on alcohol consumption, smoking, pharmaceutical use, diabetes complications, diabetes duration, physical activity, previous fractures are collected.

Participating in This Clinical Trial

Inclusion Criteria

  • Type 1 or type 2 diabetes. – Age ≥ 50 years. – Unaltered treatment of diabetes during the previous six months (no changes in drugs, but an increase or decrease in dose is accepted) and HbA1c is stable with a level of ± 1 in the same period. – HbA1c level≥ 7 % through the previous six months. – BMI between 19 og 35. Specific inclusion criteria for type 2 diabetes: – Either treatment with metformin, sulfonylureas, dipeptidyl peptidase IV (DPP IV) inhibitors or glucagon-like peptide 1 (GLP-1) analogs. – Treatment with insulin and insulin in the combination with metformin, sulfonylureas, DPP IV inhibitors or GLP-1 analogs. Exclusion Criteria:

  • HbA1C > 10% – Pregnancy. – Metal implanted at both ankles and wrists. – Patients treated with: Antiresorptive (incl. hormone replacement therapy) or bone anabolic treatment, glucocorticoids, lithium and anticonvulsives. – Patients with a bone disease other than osteoporosis. – Vertebral fracture visible by vertebral fracture assessment (VFA). – Patients with renal disease defined by estimated glomerular filtration rate(eGFR) < 50. – Other medical disease in unstable phase (fx. cancer, hyperthyroidism). – Heart failure; New York Heart Association (NYHA) class IV. – Patients which the investigator does not believe is fit to participate in the study

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Jakob Starup Linde
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Jakob Starup Linde, MD – Aarhus University Hospital
  • Overall Official(s)
    • Peter Vestergaard, Professor MD PhD DrMedSc, Principal Investigator, Aalborg University Hospital
    • Kim Brixen, Professor MD PhD DrMedSc, Principal Investigator, Odense University Hospital
    • Søren Gregersen, MD PhD, Study Chair, Aarhus University Hospital
    • Bente Lomholt Langdahl, Professor MD PhD DrMedSc, Study Chair, Aarhus University Hospital
    • Ellen-Magrethe Hauge, MD PhD, Study Chair, Aarhus University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.